California-based startup bets on AI-designed biologics that tackle complex diseases from multiple angles at once.
“Our platform gives us the ability to engineer multiple modalities into a single molecule to target a variety of disease mechanisms. Our flexible hub-and-spoke company structure lets us efficiently translate our diverse MUXBODY programs into the clinic.”
When Protuoso Biosciences co-founder Willie Xiang said this, he was describing a shift in how a growing number of scientists – and increasingly, investors – are beginning to think about disease itself.
This week, Protuoso Biosciences announced the close of an oversubscribed $9.5 million seed financing round led by Taya Venture and Darwin Ventures, with participation from NSG Ventures, SEEDS and other investors. The company plans to use the funding to advance its biologics platform across cardiometabolic disease, cancer and autoimmune conditions [1].
Underneath the announcement is a bigger idea gaining traction across medicine and longevity science: many of the diseases that define aging do not happen in isolation, so perhaps our therapies should stop treating them that way.
For decades, the pharmaceutical industry largely operated on a simple formula of identifying a single faulty pathway in the body and designing a drug to block or activate it. That model produced life-saving medicines, but it also created blind spots. Human biology is messy, interconnected and constantly adapting. Diseases like obesity, cardiovascular disease, cancer and autoimmune disorders rarely emerge from one malfunctioning switch. They are more like overlapping traffic systems where inflammation, metabolism, immune function and cellular stress all collide at once.
Many current drugs still approach those diseases one pathway at a time. Protuoso is betting that the approach is starting to look outdated.
At the center of the company’s platform are what it calls MUXBODIES, engineered biologic therapies designed to perform several coordinated functions simultaneously. Instead of acting like a single-purpose tool, these therapies are intended to behave more like multitasking systems.
An easy way to think about it is this: traditional biologics often function like a key designed to open one lock. Protuoso wants to build a therapy capable of interacting with several biological mechanisms at the same time. That may sound ambitious, but it only shows how researchers are beginning to recognize that chronic diseases linked to aging are deeply networked problems, not isolated events.
The reason companies like Protuoso are emerging now has a lot to do with advances in AI and synthetic biology. Historically, combining multiple therapeutic functions into a single biologic molecule was extraordinarily difficult. Every added function increased the complexity exponentially, making therapies harder to engineer, test and manufacture.
“Most biologics today are limited to a single mechanism or modality, as combining multiple functions into one molecule has historically been very complex to engineer,” said Dr Tim Lu, co-founder and chairman of Protuoso Biosciences. “As functionality increases, design complexity grows exponentially, which has constrained innovation. Advancements in synthetic biology, AI, and protein design have now enabled us to build a platform that reduces this complexity and achieves scalable development of multifunctional biologics.”
In practical terms, AI allows researchers to simulate and test enormous numbers of protein designs digitally before moving into physical experiments. That can dramatically shorten timelines and help scientists navigate the almost overwhelming complexity of protein engineering.
The biotech industry has spent the last few years talking about AI largely as a faster discovery engine. However, companies like Protuoso suggest the conversation is evolving. AI is increasingly enabling entirely new therapeutic architectures that were previously too difficult to build.
For us closely watching longevity research, Protuoso’s focus on cardiometabolic disease may be particularly notable. Obesity, metabolic dysfunction and chronic inflammation are increasingly viewed not simply as standalone conditions but as accelerators of biological aging itself. The downstream effects ripple outward into cardiovascular disease, immune decline and even cancer risk. That interconnected view of disease mirrors the philosophy that aging is not one process but many systems deteriorating together.
Protuoso says its cardiometabolic programs are designed to target both systemic obesity and the organ-level damage that follows. In oncology, the company is developing immune-cell engager therapies aimed at overcoming problems like immune exhaustion and short-lived responses that continue to limit many cancer treatments. At the same time, the company’s “hub-and-spoke” structure reveals another reality: efficiency matters.
Rather than building one massive pipeline under a single roof, Protuoso’s model allows programs to be advanced, partnered or spun out independently. In a tighter investment environment, that flexibility could prove just as important as the science itself.
“We’ve invested in leading healthcare funds and global biotech companies, and Protuoso reflects the qualities we look for in an early-stage life sciences platform,” said Christopher Shen, General Manager at Taya Venture. “The combination of a transformative platform technology, an experienced team with a proven track record of advancing multiple high-value assets into the clinic, and a clear path to clinical development forms a strong foundation for long-term value creation.”
Protuoso remains an early-stage company, and many hurdles still stand between platform promise and approved therapies. Still, the enthusiasm surrounding its seed round is evidence that the industry increasingly appears to focus on managing biology more holistically – addressing multiple systems, pathways and mechanisms at once.
After all, aging itself is not caused by one broken pathway; it is the accumulation of interconnected dysfunction across the body over time. And if Protuoso’s vision succeeds, medicine may look like orchestrating several biological systems together – precisely the kind of “multiple modalities in a single molecule” Xiang described at the very beginning.
